Abseamed

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
21-08-2023
Produktens egenskaper Produktens egenskaper (SPC)
21-08-2023

Aktiva substanser:

epoetin alfa

Tillgänglig från:

Medice Arzneimittel Pütter GmbH Co. KG

ATC-kod:

B03XA01

INN (International namn):

epoetin alfa

Terapeutisk grupp:

Antianemic preparations

Terapiområde:

Anemia; Kidney Failure, Chronic; Cancer

Terapeutiska indikationer:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy).Abseamed can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) 10-13 g/dl [6.2-8.1 mmol/l], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).Abseamed can be used to reduce exposure to allogeneic blood transfusions in adult non iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml.

Produktsammanfattning:

Revision: 22

Bemyndigande status:

Authorised

Tillstånd datum:

2007-08-27

Bipacksedel

                                75
B. PACKAGE LEAFLET
76
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ABSEAMED 1,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 2,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
ABSEAMED 3,000 IU/0.3 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 4,000 IU/0.4 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 5,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 6,000 IU/0.6 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 7,000 IU/0.7 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 8,000 IU/0.8 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 9,000 IU/0.9 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 10,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
ABSEAMED 20,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 30,000 IU/0.75 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 40,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
Epoetin alfa
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Abseamed is and what it is used for
2.
What you need to know before you use Abseamed
3.
How to use Abseamed
4.
Possible side effects
5.
How to store Abseamed
6.
Contents of the pack and other information
1.
WHAT ABSEAMED IS AND WHAT IT IS USED FOR
Abseamed contains the active substance epoetin alfa, a protein that
stimulates the bone marrow to
produce more red blood cells which carry haemoglobin (a substance that
transports oxygen). Epoe
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled
syringe
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled
syringe
Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled
syringe
Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled
syringe
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled
syringe
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled
syringe
Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled
syringe
Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 2,000 IU of epoetin alfa
*
corresponding to 16.8 micrograms per mL
A pre-filled syringe of 0.5 mL contains 1,000 international units (IU)
corresponding to 8.4 micrograms
epoetin alfa. *
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Each mL of solution contains 2,000 IU of epoetin alfa
*
corresponding to 16.8 micrograms per mL
A pre-filled syringe of 1 mL contains 2,000 international units (IU)
corresponding to 16.8 micrograms
epoetin alfa. *
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 10,000 IU of epoetin alfa
*
corresponding to 84.0 micrograms per mL
A pre-filled syringe of 0.3 mL contains 3,000 international units (IU)
corresponding
to 25.2 micrograms epoetin alfa. *
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 10,000 IU of epoetin alfa
*

                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 21-08-2023
Produktens egenskaper Produktens egenskaper bulgariska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 03-10-2018
Bipacksedel Bipacksedel spanska 21-08-2023
Produktens egenskaper Produktens egenskaper spanska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 03-10-2018
Bipacksedel Bipacksedel tjeckiska 21-08-2023
Produktens egenskaper Produktens egenskaper tjeckiska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 03-10-2018
Bipacksedel Bipacksedel danska 21-08-2023
Produktens egenskaper Produktens egenskaper danska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 03-10-2018
Bipacksedel Bipacksedel tyska 21-08-2023
Produktens egenskaper Produktens egenskaper tyska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 03-10-2018
Bipacksedel Bipacksedel estniska 21-08-2023
Produktens egenskaper Produktens egenskaper estniska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 03-10-2018
Bipacksedel Bipacksedel grekiska 21-08-2023
Produktens egenskaper Produktens egenskaper grekiska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 03-10-2018
Bipacksedel Bipacksedel franska 21-08-2023
Produktens egenskaper Produktens egenskaper franska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 03-10-2018
Bipacksedel Bipacksedel italienska 21-08-2023
Produktens egenskaper Produktens egenskaper italienska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 03-10-2018
Bipacksedel Bipacksedel lettiska 21-08-2023
Produktens egenskaper Produktens egenskaper lettiska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 03-10-2018
Bipacksedel Bipacksedel litauiska 21-08-2023
Produktens egenskaper Produktens egenskaper litauiska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 03-10-2018
Bipacksedel Bipacksedel ungerska 21-08-2023
Produktens egenskaper Produktens egenskaper ungerska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 03-10-2018
Bipacksedel Bipacksedel maltesiska 21-08-2023
Produktens egenskaper Produktens egenskaper maltesiska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 03-10-2018
Bipacksedel Bipacksedel nederländska 21-08-2023
Produktens egenskaper Produktens egenskaper nederländska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 03-10-2018
Bipacksedel Bipacksedel polska 21-08-2023
Produktens egenskaper Produktens egenskaper polska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 03-10-2018
Bipacksedel Bipacksedel portugisiska 21-08-2023
Produktens egenskaper Produktens egenskaper portugisiska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 03-10-2018
Bipacksedel Bipacksedel rumänska 21-08-2023
Produktens egenskaper Produktens egenskaper rumänska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 03-10-2018
Bipacksedel Bipacksedel slovakiska 21-08-2023
Produktens egenskaper Produktens egenskaper slovakiska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 03-10-2018
Bipacksedel Bipacksedel slovenska 21-08-2023
Produktens egenskaper Produktens egenskaper slovenska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 03-10-2018
Bipacksedel Bipacksedel finska 21-08-2023
Produktens egenskaper Produktens egenskaper finska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 03-10-2018
Bipacksedel Bipacksedel svenska 21-08-2023
Produktens egenskaper Produktens egenskaper svenska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 03-10-2018
Bipacksedel Bipacksedel norska 21-08-2023
Produktens egenskaper Produktens egenskaper norska 21-08-2023
Bipacksedel Bipacksedel isländska 21-08-2023
Produktens egenskaper Produktens egenskaper isländska 21-08-2023
Bipacksedel Bipacksedel kroatiska 21-08-2023
Produktens egenskaper Produktens egenskaper kroatiska 21-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 03-10-2018

Sök varningar relaterade till denna produkt

Visa dokumenthistorik